An eye-care composition solution for relieving eyestrain and its preparation method and application

Abstract

The application provides an eye-care composition solution for relieving visual fatigue and a preparation method and application thereof, and belongs to the technical field of eye-care products. The composition solution comprises the following raw materials in mass percentage: Psidium guajava fruit powder 0.4-4%; Aronia melanocarpa fruit powder 0.8-4%; dihydroquercetin 0.01-0.2%; ergothioneine 0.01-0.06%; and the balance is water. The application takes Psidium guajava fruit powder and Aronia melanocarpa fruit powder as the main body, and is supplemented by dihydroquercetin and ergothioneine for joint action, so that the antioxidant and anti-inflammatory capacity of the eye can be improved, and the tear secretion of dry eye mice can be increased. The composition of the application produces a synergistic effect between the plant extracts and the high-efficiency active ingredients through scientific proportioning, aims to simultaneously relieve visual fatigue and improve dry eye symptoms, and has high product development value.

Description

Technical Field

[0001] This invention belongs to the field of eye care product technology, specifically relating to an eye care composition solution for relieving eye fatigue, its preparation method, and its application. Background Technology

[0002] With the widespread use of video display terminals, people are spending more time using their eyes at close range, increasing visual load and significantly raising the incidence of eye fatigue and related eye problems. Dry eye syndrome, as a typical complication and important cause of eye fatigue, interacts with the eye fatigue to form a vicious cycle, seriously affecting eye health.

[0003] From a pathological perspective, modern medicine believes that dry eye syndrome is related to an imbalance in the ocular surface microenvironment, oxidative stress, and inflammatory responses: excessive eye strain leads to a decrease in blinking frequency, reduced tear film stability, and accelerated evaporation; factors such as blue light cause damage to ocular surface cells, resulting in the accumulation of reactive oxygen species, decreased activity of antioxidant enzymes, and abnormal expression of inflammatory factors, further damaging lacrimal gland function and ocular surface structure. Traditional Chinese medicine theory points out that the core pathogenesis of dry eye syndrome and eye fatigue is "disorders of the internal organs and malnourishment of the eyes," with liver blood deficiency, kidney essence insufficiency, and spleen qi weakness all leading to insufficient nourishment of the eyes and exacerbating symptoms.

[0004] Current intervention methods have limitations: Western medicine artificial tears can only provide temporary relief from dryness, and anti-inflammatory eye drops carry the risk of side effects; traditional Chinese medicine therapies require professional operation and long treatment courses, and existing Chinese herbal compositions are mostly simple combinations of common herbs, lacking rigorous animal models to verify efficacy and failing to meet the dual needs of relieving eye fatigue and intervening in dry eye syndrome. Therefore, developing safe, effective, and long-term suitable compositions is of great value. Summary of the Invention

[0005] To address the shortcomings of existing technologies, this invention provides an eye-protecting composition solution for relieving eye fatigue, its preparation method, and its application. The composition comprises guava, black chokeberry fruit, dihydroquercetin, and ergothioneine, forming an antioxidant network that provides comprehensive protection for the eyes.

[0006] To achieve the aforementioned objectives, the present invention employs the following technical solution: This invention provides an eye-care composition solution for relieving eye fatigue, which is composed of the following raw materials by mass percentage: Guava fruit powder 0.4-4%; Black chokeberry fruit powder: 0.8-4%; Dihydroquercetin 0.01~0.2%; Ergothioneine 0.01~0.06%; The remainder is water.

[0007] Guava (Psidium guajava L.), commonly known as guava, is a fruit tree belonging to the Myrtaceae family. Due to its nutritional value, guava is considered one of the "superfruits." Guava is rich in various phytochemicals, such as polyphenols, flavonoids, isoflavones, tannins, phenolic acids, terpenes, saponins, lectins, essential oils, and fatty acids. Polyphenols can achieve anti-inflammatory effects through multiple mechanisms, including scavenging oxygen free radicals, altering cellular redox states, resisting lipid peroxidation, inhibiting neutrophil extravasation, and reducing the production of inflammatory factors. Furthermore, lycopene, a major component of raw guava fruit and a carotenoid compound, exhibits anti-inflammatory and antioxidant properties by reducing acute inflammatory responses in mice.

[0008] Aronia melanocarpa (Michx.) Elliott, a black-fruited chokeberry, is rich in anthocyanins, proanthocyanidins, flavonols, and other polyphenolic active substances. Aronia melanocarpa fruit extract exhibits excellent antioxidant activity, effectively scavenging free radicals in the body and reducing oxidative stress damage. Simultaneously, this extract demonstrates significant anti-inflammatory properties, inhibiting the activation of inflammatory signaling pathways such as nuclear factor-κB and downregulating the expression of key pro-inflammatory factors such as tumor necrosis factor-α and interleukin-6.

[0009] Guava and black chokeberry, rich in bioactive compounds, are considered to have powerful antioxidant and anti-inflammatory effects. Widely used in pharmaceuticals, cosmetics, and functional foods, they are considered a natural and valuable source of phytonutrients, thus becoming superfoods.

[0010] Dihydroquercetin, also known as taxol, is a flavonoid. Flavonoids are important compounds in many plants, possessing the ability to chelate transition metal ions, scavenge free radicals, and interact with enzymes that have been proven to be effective antioxidants. Dihydroquercetin, a flavonoid compound, has also been shown to be a potent antioxidant. Studies have found that, at the same dosage, the antioxidant activity of dihydroquercetin is 3.4–4.9 times higher than that of quercetin. Furthermore, it also exhibits excellent anti-inflammatory activity; several researchers have reported that dihydroquercetin exerts its anti-inflammatory effects by regulating the NF-κB signaling pathway.

[0011] Ergothioneine (ERG) is a rare thiohistidine betaine amino acid with potent antioxidant activity. It is synthesized by various microorganisms, particularly fungi (including mushroom fruiting bodies) and actinomycetes, but plants and animals cannot synthesize it and obtain it from soil and food, respectively. It has multiple physiological functions, including scavenging free radicals, anti-inflammation, maintaining DNA biosynthesis, and normal cell growth. Ergothioneine has applications in various fields, such as as a food additive to enhance the antioxidant capacity of food. Due to its antioxidant and anti-inflammatory effects, ergothioneine is often added to skincare products for anti-aging, whitening, and improving skin tone. As a dietary supplement, ergothioneine helps enhance the body's antioxidant capacity and maintain health.

[0012] However, although each component has beneficial effects on relieving eye fatigue and protecting eye health, whether directly or indirectly, the effect of a single component is often limited. Therefore, a combination of multiple eye-protecting ingredients is scientifically formulated to form an antioxidant network that provides comprehensive protection for the eyes.

[0013] In a preferred embodiment of the present invention, the eye-protecting composition solution comprises, by weight percentage, the following raw materials: Guava fruit powder 2.2%; Black chokeberry fruit powder 1.1%; Dihydroquercetin 0.19%; Ergothioneine 0.05%; The remainder is water.

[0014] Furthermore, the guava fruit powder contains an active ingredient and a carrier, wherein the active ingredient is ≥90 wt%, and the active ingredient is dried guava juice or an aqueous extract of guava fruit; the black chokeberry fruit powder contains an active ingredient and a carrier, wherein the active ingredient is ≥90 wt%, and the active ingredient is dried black chokeberry juice or an aqueous extract of black chokeberry fruit.

[0015] Furthermore, the carrier is maltodextrin.

[0016] This invention also provides a method for preparing the aforementioned eye-protecting composition solution, specifically comprising the following steps: passing four raw materials—guava fruit powder, black chokeberry fruit powder, dihydroquercetin, and ergothioneine—through a 120-mesh sieve; weighing the sieved raw materials—guava fruit powder, black chokeberry fruit powder, dihydroquercetin, and ergothioneine—in an 85°C aqueous solution, first dissolving dihydroquercetin, then dissolving ergothioneine, and finally dissolving guava fruit powder and black chokeberry fruit powder. After all raw materials are completely dissolved and dispersed, the eye-protecting composition solution is prepared. This invention also provides an application of the aforementioned composition solution in the preparation of products or formulations for relieving eye fatigue.

[0017] Furthermore, the product is a pharmaceutical, health food, special medical purpose formula food, ordinary food, or dietary supplement.

[0018] Furthermore, when the product is a pharmaceutical product, its dosage form includes solutions, granules, tablets, capsules, suspensions, or pills; when the product is a common food or dietary supplement, its form includes powders, solid beverages, chewable tablets, gummies, or drinks.

[0019] Furthermore, the formulation is a topical ophthalmic drug delivery formulation; wherein, the topical ophthalmic drug delivery formulation is an eye drop, an ophthalmic gel, or an ophthalmic ointment.

[0020] Compared with the prior art, the present invention has the following beneficial effects: This invention provides a composition containing guava fruit powder and black chokeberry fruit powder to promote eye health. Specifically, the composition promotes eye health by relieving eye fatigue and improving dry eye syndrome. The composition for relieving eye fatigue is a compound of guava fruit powder, black chokeberry fruit powder, dihydroquercetin, and ergothioneine. The guava fruit powder and black chokeberry fruit powder are rich in anthocyanins, proanthocyanidins, flavonols, and other polyphenolic active substances. The hydroxyl groups (–OH) on the aromatic rings of these phenolic compounds are reactive and responsible for antioxidant activity. The flavonoids dihydroquercetin and ergothioneine (ERG) have also been shown to have strong antioxidant activity, capable of scavenging free radicals, reducing inflammation, and maintaining DNA biosynthesis and normal cell growth. From a modern medical perspective, eye fatigue is caused by damage resulting from the ineffective removal of free radicals generated in the eyes. Each of the four ingredients has antioxidant and free radical scavenging effects on its own. The four components complement each other and have a potential synergistic effect in terms of anti-oxidation and anti-inflammation.

[0021] Furthermore, the combination of four ingredients not only comprehensively enhances the composition's efficacy in eye protection, but the addition of two fruit powders further reduces the addition and intake of the monomeric compounds dihydroquercetin and ergothioneine, improving formula safety while reducing costs. Regarding ingredient safety and regulations, guava fruit powder and black chokeberry fruit powder are derived from food-grade raw materials, dihydroquercetin is a new resource food, and ergothioneine (ET) is permitted by EFSA and FDA for use as a food additive and supplement. Therefore, this formula offers certain guarantees in terms of ingredient safety and regulations, possessing good feasibility and industrialization prospects. Attached Figure Description

[0022] Figure 1The graph shows the tear content results of mice in different groups. * indicates the statistical difference between the model group and the normal control group, # indicates the statistical difference between different drug treatment groups and the model group, ***P<0.001; #P<0.05.

[0023] Figure 2 The figures show the results of serum venous levels of oxidative factors T-AOC, GSH-Px, and SOD in mice from different groups. Figure A shows the T-AOC level, Figure B shows the GSH-Px level, and Figure C shows the SOD level. * indicates statistical difference between the model group and the normal control group, # indicates statistical difference between different treatment groups and the model group, and *P<0.05, ****P<0.0001, #P<0.05, ##P<0.01, ###P<0.001, ####P<0.0001.

[0024] Figure 3 The levels of the inflammatory factor IL-1β in the serum of mice in different groups were measured. * indicates the statistical difference between the model group and the normal control group, # indicates the statistical difference between different drug administration groups and the model group, ****P<0.0001, ##P<0.01, ###P<0.001.

[0025] Figure 4 Figure 1 shows the results of mRNA expression levels of inflammatory factors IL-1β, IL17, and IFNγ in the eyes of mice from different groups. Figure A shows the relative mRNA expression levels of IL-1β, Figure B shows the relative mRNA expression levels of IL17, and Figure C shows the relative mRNA expression levels of IFNγ. **P<0.01, #P<0.05, ##P<0.01, ###P<0.001, ####P<0.0001; * indicates statistical difference between the model group and the normal control group, and # indicates statistical difference between different treatment groups and the model group.

[0026] Figure 5 This is a representative image of HE staining of mouse eyeballs. Detailed Implementation

[0027] To further illustrate the technical means and effects of the present invention, the following description, in conjunction with preferred embodiments, further explains the technical solution of the present invention. However, the present invention is not limited to the scope of these embodiments. Unless otherwise specified, the experimental reagents, raw materials, and instruments designed in the embodiments, comparative examples, and effect examples of the present invention are prepared by conventional means or purchased through commercial channels.

[0028] All experimental results in this study are expressed as mean ± standard deviation (s). Statistical analysis of inter-group differences was performed using GraphPad Prism software, and ANOVA was used for statistical analysis. P < 0.05 indicated a statistically significant difference, and P < 0.01 indicated a statistically significant difference.

[0029] The specific embodiments and comparative examples involve the following raw material sources: Guava fruit powder, composed of 90 wt% dried guava juice or a mixture of aqueous extract of guava fruit and 10 wt% maltodextrin, was purchased from Xi'an Longze Biotechnology Co., Ltd.; Black chokeberry fruit powder, composed of 90 wt% dried black chokeberry juice or a mixture of aqueous extract of black chokeberry fruit and 10 wt% maltodextrin, was purchased from Xi'an Longze Biotechnology Co., Ltd.; Dihydroquercetin, product number T196224, was purchased from Shanghai Aladdin Biochemical Technology Co., Ltd.; Ergothioneine, product number L864254, was purchased from Shanghai Maclean Biochemical Technology Co., Ltd.

[0030] The reagents used were sourced as follows: IL-6 enzyme-linked immunosorbent assay kit (purchased from Wuhan Elite Biotechnology Co., Ltd.), IL-1β enzyme-linked immunosorbent assay kit (purchased from Wuhan Elite Biotechnology Co., Ltd.), TNF-α enzyme-linked immunosorbent assay kit (purchased from Wuhan Elite Biotechnology Co., Ltd.), Total antioxidant capacity (T-AOC) assay kit (ABTS method) (purchased from Nanjing Jiancheng Bioengineering Institute), Glutathione peroxidase (GSH-PX) assay kit (purchased from Nanjing Jiancheng Bioengineering Institute), Total superoxide dismutase (T-SOD) assay kit (purchased from Nanjing Jiancheng Bioengineering Institute), Eastep™ Super Total RNA Extraction Kit (RNA extraction kit) (purchased from Zhejiang Promeg Biotechnology Co., Ltd.), HiScript IV All-in-One Ultra RT SuperMix reverse transcription kit (purchased from Nanjing Novizan Biotechnology Co., Ltd.), Taq Pro UniversalSYBR qPCR Master Mix (purchased from Nanjing Novizan Biotechnology Co., Ltd.), PBS buffer (purchased from White Shark Biotechnology), and eye fixative (purchased from Wuhan Saive Biotechnology Co., Ltd.).

[0031] The experimental animals used were male Balb / c mice, aged 6-8 weeks, weighing 22-25g, and SPF grade. They were purchased from Zhejiang Vital River Laboratory Animal Technology Co., Ltd. They were routinely housed in an environment maintained at 23±1℃, relative humidity 45±5%, and a light cycle of 12h, and were provided with normal food and drinking water daily. The mice underwent an acclimatization diet for one week before the start of the experiment. All experimental procedures followed the Animal Care and Use Guidelines of the Animal Research Institute Committee of Zhejiang University. The preparation methods of the eye-protecting composition solutions for relieving eye fatigue described in Examples 1-4 and Comparative Examples 1-2 are as follows: Step 1: Sieve the raw materials. Sieve the four raw material powders through a 120-mesh sieve to remove any lumpy raw materials. Step 2: Weighing raw materials and preparing solution. Pour a certain amount of aqueous solution into a stirring cup equipped with a stirring device and temperature control system. Set the stirring speed to 300 r / min and the temperature to 85℃. First, add the weighed dihydroquercetin powder. After it is completely dissolved, add the formula weight of ergothioneine and stir to dissolve. Finally, add guava fruit powder and black chokeberry fruit powder. After they are completely dissolved and dispersed, the composition solution can be obtained.

[0032] The mass percentages of each component added are shown in Examples 1-4 and Comparative Examples 1-2, as detailed in Table 1.

[0033] Table 1. Percentage of raw material mass (%) in Examples 1-4 and Comparative Examples 1-2

[0034] Example 1 An embodiment of the eye-protecting composition solution and its preparation method of the present invention comprises the following raw materials in weight percentage: guava fruit powder 0.4%; black chokeberry fruit powder 0.8%; dihydroquercetin 0.01%; ergothioneine 0.01%; and the balance being water.

[0035] Example 2 An embodiment of the eye-protecting composition and its preparation method of the present invention, wherein the eye-protecting composition solution comprises the following raw materials in weight percentages: guava fruit powder 2.2%; black chokeberry fruit powder 1.1%; dihydroquercetin 0.19%; ergothioneine 0.05%; and the balance being water.

[0036] Example 3 An embodiment of the eye-protecting composition and its preparation method of the present invention, wherein the eye-protecting composition solution comprises the following raw materials in weight percentage: guava fruit powder 2.2%; black chokeberry fruit powder 2.1%; dihydroquercetin 0.2%; ergothioneine 0.06%; and the balance being water.

[0037] Example 4 An embodiment of the eye-protecting composition and its preparation method of the present invention comprises the following raw materials in weight percentage: 4% guava fruit powder; 4% black chokeberry fruit powder; 0.2% dihydroquercetin; 0.06% ergothioneine; and the balance being water.

[0038] Comparative Example 1 An embodiment of the eye-protecting composition and its preparation method of the present invention involves adding only 4% by weight of guava fruit powder, with the remainder being water.

[0039] Comparative Example 2 An embodiment of the eye-protecting composition and its preparation method of the present invention is provided, wherein the eye-protecting composition solution comprises 4% by weight of black chokeberry fruit powder and 0.2% by weight of dihydroquercetin, with the balance being water.

[0040] Example 5 Establishment and administration of a mouse dry eye model.

[0041] Preparation of 0.2% benzalkonium chloride (BAC) solution: Weigh 0.2g of benzalkonium chloride powder and add it to a beaker containing 99.8ml of physiological saline. Dissolve by sonication for 10-20min to obtain a 0.2% benzalkonium chloride solution.

[0042] The mass percentages of each component added are shown in Examples 1-4 and Comparative Examples 1-2. The raw material components were mixed according to the proportions in Table 1 to obtain the solutions of each composition.

[0043] After 7 days of adaptive feeding, healthy mice were randomly divided into the following groups: blank control group (physiological saline), model control group (0.2% BAC), and drug treatment groups: Examples 1-4 and Comparative Examples 1-2.

[0044] The experimental drug was a combination obtained by mixing Examples 1-4 and Comparative Examples 1-2 above; the modeling drug was benzalkonium chloride, purchased from Sigma-Aldrich.

[0045] In both the model group and the drug-treated group, 5 μL of 0.2% benzalkonium chloride (BAC) solution was instilled into the conjunctival sacs of mice twice daily for 14 days to induce a mouse dry eye model. The normal control group received an equal volume of physiological saline. During the 14-day dry eye model establishment period, mice in the drug-treated group were orally administered a combination solution with different mass ratios at a dose of 10 mL / kg daily, with 6 mice per group (n=6). Mice in the control and model groups were orally administered an equal volume of aqueous solution. All mice were kept under normal environmental conditions throughout the experiment. After 14 days, tear secretion was measured using phenol red cotton thread. Subsequently, the mice were sacrificed, dissected, and tissue samples were collected to measure other indicators.

[0046] Example 6 Measurement of basal tear secretion.

[0047] Basal tear secretion in mice was measured at the same time point (2 pm) for each group of mice. 2 ml of isoflurane was injected onto a defatted cotton ball, which was placed in the lower compartment of the tube tip container. The container lid was closed to allow the isoflurane to evaporate fully. The mice were then placed in the container. After 10-20 seconds, the mice were successfully anesthetized. The lower eyelid was then gently pulled back to expose the lower conjunctival sac. One end of a phenol red cotton thread was bent approximately 1 mm and placed in the inner 1 / 3 of the lower eyelid conjunctival sac. After 15 seconds, the thread was removed, and the length of the red portion soaked in tear fluid was measured. After the test, the mice's eyes were assisted in closing to avoid excessive exposure and ocular surface irritation.

[0048] The results of the tear secretion test showed that... Figure 1 As shown, the results indicated that the tear content of the model group mice was significantly reduced compared to the control group. Examples 1, 2, and 3 significantly increased the tear content of mice with dry eye syndrome, while Example 4 showed a trend of increasing tear secretion. The tear secretion of mice in Comparative Example 1 and Comparative Example 2 groups did not show a significant increase.

[0049] Example 7 Determination of T-AOC, SOD and GSH-Px in mouse serum.

[0050] The mice in Example 5 were dissected, and eyeballs were removed. Periocular venous blood was collected, centrifuged at 3000 rpm and 4°C for 10 min, and the serum was separated, aliquoted, and stored at -20°C for later use. The levels of T-AOC, SOD, and GSH-Px in the serum were measured according to the kit instructions. The results are as follows: Figure 2 As shown.

[0051] Figure 2 The results showed that, compared with the normal control group, the serum T-AOC, GSH-Px, and SOD activities were significantly reduced in the benzalkonium chloride eye drop model group mice (P<0.01), indicating that the model group mice had a high level of oxidative damage, leading to a decrease in the level of antioxidant stress factors. Figure 2 As shown in Figure A, compared with the model control group, the T-AOC content in all four groups (Examples 1-4) was increased to varying degrees. Except for Example 4, the other three groups significantly increased the serum T-AOC content. Notably, Example 2 showed the strongest increase, while Comparative Examples 1 and 2 did not show significant increases in T-AOC content compared to the examples. GSH-Px content results are shown below. Figure 2 B. Compared with the model group, Examples 1, 2, and 3 showed increased GSH-Px levels, with Example 2 significantly increasing GSH-Px levels in mouse serum. SOD levels were also observed... Figure 2C. Compared with the model group, the SOD content of all the example groups increased. Among them, the SOD enhancement effects of Example 2 and Example 3 were significantly different, and the SOD level of Example 2 was better than that of Example 3. Comparative Example 1 and Comparative Example 2 did not improve the serum SOD content of dry eye mice.

[0052] The above results indicate that the composition solution prepared in Example 2 has the best antioxidant capacity.

[0053] Example 8 Measurement of serum inflammatory factor IL-1β in periorbital veins of mice and measurement of relative mRNA expression levels of inflammatory factors IL-1β, IL17 and IFNγ in the eyeball.

[0054] Fourteen days after drug administration, mice in each group were dissected, and periorbital venous blood was collected. Serum was separated, and serum IL-1β levels were measured using enzyme-linked immunosorbent assay (ELISA). OD450 values ​​were measured using a microplate reader. The standard curve equation was obtained as y = 136.37x - 2.9238, R0. 2 = 0.9926, which can be substituted into the standard curve to calculate its corresponding concentration. The results of the measurement of the inflammatory factor IL-1β in mouse serum are shown below. Figure 3 Compared with the blank group, the IL-1β content in the model group mice was significantly increased. Compared with the model group, the IL-1β content in the serum of mice in Examples 1, 2, 3 and Comparative Example 1 was significantly reduced after administration of the active ingredient composition.

[0055] Fourteen days after drug administration, mice were euthanized, and the entire eyeball was immediately removed. The eyeball was rinsed thoroughly in physiological saline and placed in a 1.5 ml imported centrifuge tube free of RNase and DNase. Lysis buffer and magnetic beads were added, and the mouse tissue was homogenized using a tissue homogenizer. Subsequent steps followed the kit instructions to extract RNA from the mouse eyeball, and the concentration and purity of the RNA were determined. Reverse transcription and real-time quantitative PCR experiments were performed according to the instructions of the reverse transcription kit purchased from Novizan. The experimental results are as follows: Figure 4 As shown.

[0056] Figure 4 The results showed that, compared with the blank group, the levels of IL-1β, IL17, and IFNγ mRNA in the model group mice were significantly increased. Compared with the model group, the expression levels of inflammatory factors IL-1β, IL17, and IFNγ mRNA in the ocular tissues of mice in Examples 1, 2, and 3 were significantly decreased. However, Comparative Examples 1 and 2 did not significantly reduce the mRNA levels of the three inflammatory factors IL-1β, IL17, and IFNγ. These results indicate that the active ingredient composition provided by this invention can effectively reduce the expression of inflammatory factors in mice and ocular tissues, exhibiting a good anti-inflammatory effect.

[0057] Example 9 After tear testing, mouse ocular tissue was obtained by dissection using ophthalmic forceps. The eyeballs were fixed in a fixative solution for 24 hours, then dehydrated and embedded in paraffin. Hematoxylin-eosin staining (HE) was performed, and the pathological changes in the mouse ocular tissue were observed using an optical microscope. The results are as follows: Figure 5 As shown.

[0058] HE staining of the corneas of mice in the control group showed a thick, well-layered corneal epithelium with 4-5 layers. The basal cells were arranged in a columnar pattern, while the stromal cells were tightly packed, with no obvious pathological features. In the model group, the corneal epithelial structure was irregular, the corneal epithelial layer was significantly thinner, the basal cells were disordered, the number of epithelial cell layers was reduced, and the corneal surface was rough. Compared to the model group, the effects were less pronounced in the example group. The pathological features of the corneas in the comparative group were still more obvious. The corneal epithelium in the example group was thickened, and the epithelial cells were more neatly arranged. The corneal epithelium in Comparative Examples 1 and 2 showed no significant changes compared to the model group, and the irregularity of the corneal epithelium in Comparative Example 2 was more pronounced, indicating that the example group was superior to the comparative group in improving the pathological changes of the corneal epithelium in mice with dry eye.

[0059] The above embodiments are only used to illustrate the design concept and features of the present invention, and their purpose is to enable those skilled in the art to understand the content of the present invention and implement it accordingly. The protection scope of the present invention is not limited to the above embodiments. Therefore, all equivalent changes or modifications made based on the principles and design ideas disclosed in the present invention are within the protection scope of the present invention.

Claims

1. An eye-protecting composition solution for relieving eye fatigue, characterized in that, By weight percentage, it consists of the following raw materials: Guava fruit powder 0.4-4%; Black chokeberry fruit powder: 0.8-4%; Dihydroquercetin 0.01~0.2%; Ergothioneine 0.01~0.06%; The remainder is water.

2. The eye-protecting composition solution as described in claim 1, characterized in that, By weight percentage, it consists of the following raw materials: Guava fruit powder 2.2%; Black chokeberry fruit powder 1.1%; Dihydroquercetin 0.19%; Ergothioneine 0.05%; The remainder is water.

3. The eye-protecting composition solution according to any one of claims 1-2, characterized in that, The guava fruit powder contains active ingredients and a carrier, wherein the active ingredients are ≥90 wt% and are dried guava juice or water extract of guava fruit.

4. The eye-protecting composition solution according to any one of claims 1-2, characterized in that, The black chokeberry fruit powder contains active ingredients and a carrier, wherein the active ingredients are ≥90 wt%, and the active ingredients are dried black chokeberry juice or water extract of black chokeberry fruit.

5. The eye-protecting composition solution according to any one of claims 3-4, characterized in that, The carrier is maltodextrin.

6. A method for preparing the eye-protecting composition solution according to any one of claims 1-5, characterized in that, Includes the following steps: Step 1: Pass the four raw materials—guava fruit powder, black chokeberry fruit powder, dihydroquercetin, and ergothioneine—through a 120-mesh sieve. Step 2: Weigh the sieved raw materials guava fruit powder, black chokeberry fruit powder, dihydroquercetin, and ergothioneine separately. Dissolve dihydroquercetin first in an 85°C aqueous solution, then dissolve ergothioneine, and finally dissolve guava fruit powder and black chokeberry fruit powder. After all raw materials are completely dissolved and dispersed, an eye protection composition solution is prepared.

7. The use of the composition solution according to any one of claims 1-5 in the preparation of products or formulations for relieving eye fatigue.

8. The application according to claim 7, characterized in that, The products mentioned for relieving eye fatigue are pharmaceuticals, health foods, special medical purpose formula foods, ordinary foods, or dietary supplements.

9. The application according to claim 8, characterized in that, When the product for relieving eye fatigue is a medicine, its dosage form includes solution, granules, tablets, capsules, suspension or pills; when the product for relieving eye fatigue is a common food or dietary supplement, its form includes powder, solid beverage, chewable tablet, gummy or drink.

10. The application according to claim 7, characterized in that, The formulation is a topical ophthalmic preparation; wherein, the topical ophthalmic preparation is an eye drop, an ophthalmic gel, or an ophthalmic ointment.

Images